Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Infection ; 47(4): 655-659, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30809760

RESUMO

OBJECTIVES: In endemic countries with a high level of chloroquine resistance, Plasmodium vivax malaria is associated with high morbidity and mortality. In these areas, the dihydroartemisinin-piperaquine combination resulted in clinical response, a more rapid clearance of parasitaemia, compared to chloroquine therapies, and reduction of recrudescence or reinfection. METHODS: We describe five cases of Plasmodium vivax malaria in returning travelers treated with dihydroartemisinin-piperaquine. RESULTS: All patients showed the early parasite clearance and no side effects. Our preliminary results suggest that the dihydroartemisinin-piperaquine combination is effective and safe even in imported cases. CONCLUSIONS: A unified treatment policy using the artemisinin combination therapy should be adopted even in non-endemic countries and larger studies are underway to support this strategy.


Assuntos
Antimaláricos/uso terapêutico , Artemisininas/uso terapêutico , Malária Vivax/tratamento farmacológico , Primaquina/uso terapêutico , Adulto , Quimioterapia Combinada/estatística & dados numéricos , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
2.
BMC Infect Dis ; 19(1): 882, 2019 Oct 22.
Artigo em Inglês | MEDLINE | ID: mdl-31640579

RESUMO

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) requires lengthy use of second-line drugs, burdened by many side effects. Hepatitis C virus (HCV) chronic infection increases risk of drug-induced liver injury (DILI) in these patients. Data on MDR-TB patients with concurrent HCV chronic infection treated at the same time with second-line antitubercular drugs and new direct-acting antivirals (DAAs) are lacking. We evaluate if treating at the same time HCV infection and pulmonary MDR-TB is feasible and effective. CASES PRESENTATION: In this study, we described two cases of patients with pulmonary MDR-TB and concurrent HCV chronic infection cured with DAAs at a Tertiary Infectious Diseases Hospital in Italy. During antitubercular treatment, both patients experienced a DILI before treating HCV infection. After DAAs liver enzymes normalized and HCV RNA was undetectable. Then antitubercular regimen was started according to the institutional protocol, drawn up following WHO MDR-TB guidelines. It was completed without further liver side effects and patients were declared cured from both HCV infection and MDR-TB. CONCLUSIONS: We suggest to consider treatment of chronic hepatitis C with DAAs as a useful intervention for reintroduction of second-line antitubercular agents in those patients who developed DILI, reducing the risk of treatment interruption when re-exposed to these drugs.


Assuntos
Antituberculosos/uso terapêutico , Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Idoso , Antituberculosos/efeitos adversos , Antivirais/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/enzimologia , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Feminino , Hepacivirus/genética , Humanos , Itália , Masculino , RNA Viral/sangue , Retratamento , Resultado do Tratamento , Tuberculose Resistente a Múltiplos Medicamentos/virologia , Tuberculose Pulmonar/virologia
3.
BMC Infect Dis ; 18(1): 212, 2018 05 08.
Artigo em Inglês | MEDLINE | ID: mdl-29739357

RESUMO

BACKGROUND: Chagas disease (CD) is a systemic parasitic infection caused by the protozoan Trypanosoma cruzi, whose chronic phase may lead to cardiac and intestinal disorders. Endemic in Latin America where it is transmitted mainly by vectors, large-scale migrations to other countries have turned CD into a global health problem because of its alternative transmission routes through blood transfusion, tissue transplantation, or congenital. Aim of this study was to compare the performance of two commercially available tests for serological diagnosis of CD in a group of Latin American migrants living in a non-endemic setting (Rome, Italy). The study was based on a cross-sectional analysis of seroprevalence in this group. Epidemiological risk factors associated to CD were also evaluated in this study population. METHODS: The present study was conducted on 368 subjects from the Latin American community resident in Rome. Following WHO guidelines, we employed a diagnostic strategy based on two tests to detect IgG antibodies against T. cruzi in the blood (a lysate antigen-based ELISA and a chemiluminescent microparticle CMIA composed of multiple recombinant antigens), followed by a third test (an immunochromatographic assay) on discordant samples. RESULTS: Our diagnostic approach produced 319/368 (86.7%) concordant negative and 30/368 (8.1%) concordant positive results after the first screening. Discrepancies were obtained for 19/368 (5.2%) samples that were tested using the third assay, obtaining 2 more positive and 17 negative results. The final count of positive samples was 32/368 (8.7% of the tested population). Increasing age, birth in Bolivia, and previous residence in a mud house were independent factors associated with T. cruzi positive serology. CONCLUSIONS: Serological diagnosis of CD is still challenging, because of the lack of a reference standard serological assay for diagnosis. Our results reaffirm the importance of performing CD screening in non-endemic countries; employing a fully automated and highly sensitive CMIA assay first could be a cost- and resource-effective strategy for mass screening of low-risk patients. However, our results also suggest that the WHO strategy of using two different serological assays, combined with epidemiological information, remains the best approach for patients coming from endemic countries.


Assuntos
Doença de Chagas/diagnóstico , Ensaio de Imunoadsorção Enzimática/métodos , Imunoensaio/métodos , Adulto , Anticorpos Antiprotozoários/sangue , Doença de Chagas/parasitologia , Estudos Transversais , Feminino , Humanos , América Latina/etnologia , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Cidade de Roma/epidemiologia , Estudos Soroepidemiológicos , Migrantes , Trypanosoma cruzi/imunologia , Estados Unidos
4.
BMC Infect Dis ; 13: 162, 2013 Apr 04.
Artigo em Inglês | MEDLINE | ID: mdl-23556433

RESUMO

BACKGROUND: In recent years, Nocardia farcinica has been reported to be an increasingly frequent cause of localized and disseminated infections in the immunocompromised patient. However, recent literature is limited. We report a case of left thigh phlegmon caused by N. farcinica that occurred in a patient with leprosy undergoing treatment with prednisone for leprosy reaction. CASE PRESENTATION: We describe the case of left thigh phlegmon caused by Nocardia farcinica in a 54-year-old Italian man affected by multi-bacillary leprosy. The patient had worked in South America for 11 years. Seven months after his return to Italy, he was diagnosed with leprosy and started multi-drug antibiotic therapy plus thalidomide and steroids. Then, during therapy with rifampicin monthly, minocycline 100 mg daily, moxifloxacin 400 mg daily, and prednisone (the latter to treat type 2 leprosy reaction), the patient complained of high fever associated with erythema, swelling, and pain in the left thigh. Therefore, he was admitted to our hospital with the clinical suspicion of cellulitis. Ultrasound examination and Magnetic Resonance Imaging showed left thigh phlegmon. He was treated with drainage and antibiotic therapy (meropenem and vancomycin replaced by daptomycin). The responsible organism, Nocardia farcinica, was identified by 16S rRNA sequencing in the purulent fluid taken out by aspiration. The patient continued treatment with intravenous trimethoprim/sulfamethoxazole and imipenem followed by oral trimethoprim/sulfamethoxazole and moxifloxacin. A whole-body computed tomography did not reveal dissemination to other organs like the lung or brain.The patient was discharged after complete remission. Oral therapy with trimethoprim/sulfamethoxazole, moxifloxacin, rifampicin monthly, clofazimine and thalidomide was prescribed to be taken at home. One month after discharge from the hospital the patient is in good clinical condition with complete resolution of the phlegmon. CONCLUSION: N. farcinica is a rare infectious agent that mainly affects immunocompromised patients. Presentation of phlegmon only without disseminated infection is unusual, even in these kinds of patients. In any case, a higher index of suspicion is needed, as diagnosis can easily be missed due to the absence of characteristic symptoms and the several difficulties usually encountered in identifying the pathogen.


Assuntos
Celulite (Flegmão)/microbiologia , Celulite (Flegmão)/patologia , Hanseníase/complicações , Nocardiose/diagnóstico , Nocardiose/patologia , Nocardia/isolamento & purificação , Coxa da Perna/patologia , Antibacterianos/uso terapêutico , Celulite (Flegmão)/tratamento farmacológico , Celulite (Flegmão)/cirurgia , DNA Bacteriano/química , DNA Bacteriano/genética , DNA Ribossômico/química , DNA Ribossômico/genética , Drenagem , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Itália , Hanseníase/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Nocardiose/tratamento farmacológico , Nocardiose/cirurgia , Prednisona/efeitos adversos , Prednisona/uso terapêutico , RNA Ribossômico 16S/genética , Análise de Sequência de DNA , Resultado do Tratamento
5.
Malar J ; 11: 91, 2012 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-22453057

RESUMO

Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines. Nevertheless, several cases of haemolytic anaemia due to i.v. artesunate treatment have been reported. This paper describes the case of an HIV-infected patient with severe falciparum malaria who was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.The patient presented with fever, headache, and arthromyalgia after returning from Central African Republic where he had been working. The blood examination revealed acute renal failure, thrombocytopaenia and hypoxia. Blood for malaria parasites indicated hyperparasitaemia (6%) and Plasmodium falciparum infection was confirmed by nested-PCR. Severe malaria according to the laboratory WHO criteria was diagnosed. A treatment with quinine and doxycycline for the first 12 hours was initially administered, followed by arthemeter/lumefantrine (Riamet(®)) for a further three days. At day 10, a diagnosis of severe haemolytic anaemia was made (Hb 6.9 g/dl, LDH 2071 U/l). Hereditary and autoimmune disorders and other infections were excluded through bone marrow aspiration, total body TC scan and a wide panel of molecular and serologic assays. The patient was treated by transfusion of six units of packed blood red cell. He was discharged after complete remission at day 25. At present, the patient is in a good clinical condition and there is no evidence of haemolytic anaemia recurrence.This is the first report of haemolytic anaemia probably associated with oral artemether/lumefantrine. Further research is warranted to better define the adverse events occurring during combination therapy with artemisinin derivatives.


Assuntos
Anemia Hemolítica/etiologia , Antimaláricos/efeitos adversos , Artemisininas/efeitos adversos , Quimioterapia Combinada/efeitos adversos , Etanolaminas/efeitos adversos , Fluorenos/efeitos adversos , Malária Falciparum/tratamento farmacológico , Administração Oral , Adulto , Anemia Hemolítica/fisiopatologia , Antimaláricos/administração & dosagem , Combinação Arteméter e Lumefantrina , Artemisininas/administração & dosagem , Coinfecção , Combinação de Medicamentos , Eritrócitos/efeitos dos fármacos , Etanolaminas/administração & dosagem , Fluorenos/administração & dosagem , HIV/fisiologia , Infecções por HIV/virologia , Hemólise , Humanos , Malária Falciparum/parasitologia , Masculino , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/fisiologia , Índice de Gravidade de Doença
6.
Travel Med Infect Dis ; 6(4): 205-9, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18571110

RESUMO

BACKGROUND: The pathogenesis of malaria is the result of complex interactions between parasites, host and environment. Several studies have assessed the role of genetic characteristics of Plasmodium falciparum infection in the clinical severity of malaria infection comparing different genotypic determinants in mild and severe cases. The genes encoding the polymorphic merozoite surface proteins 1 (msp-1) and 2 (msp-2) and the dihydrofolate reductase (dhfr) of malaria parasites have been extensively used as markers to investigate the genetic diversity and the population structure of P. falciparum. The aim of this study was to assess the epidemiological, clinical, host- and parasite-related determinant factor of the genetic diversity of P. falciparum infections in travellers returning to Italy. METHODS: Between 1998 and 2001, we have retrospectively studied 64 inpatients all returning from African malaria-endemic countries. Designation of severe malaria was determined by using the World Health Organization (WHO) definition. P. falciparum infections detected by species-specific PCR were genotyped at the msp-1 and msp-2 loci and clones were determined. PCR and enzyme-digestion methods were used to screen the mutation occurring at codon 108. RESULTS: Multiple P. falciparum genotypes were detected in 32 patients (50%). The number of genotypes was correlated to different host characteristics. No association was found between allelic number of msp-1 or msp-2 and season of travel, absence of antimalarial prophylaxis, length of stay or blood parasitemia. At multiple analysis adjusted for few confounding variables, two variables showed a significant association with multiplicity of P. falciparum genotypes: male gender (p=0.018) and severity of disease (p=0.044). CONCLUSION: In our study all but one patients with severe malaria had a infection with a multiplicity of P. falciparum clones. At multivariate analysis the male gender, and the occurrence of severe malaria were significantly more commonly detected in patients affected by imported malaria with multiple clones.


Assuntos
Malária Falciparum/epidemiologia , Malária Falciparum/fisiopatologia , Índice de Gravidade de Doença , Viagem , Adulto , África , Animais , DNA de Protozoário/análise , Feminino , Genótipo , Humanos , Itália/epidemiologia , Malária Falciparum/parasitologia , Masculino , Proteína 1 de Superfície de Merozoito/genética , Pessoa de Meia-Idade , Plasmodium falciparum/classificação , Plasmodium falciparum/genética , Plasmodium falciparum/isolamento & purificação , Plasmodium falciparum/patogenicidade , Reação em Cadeia da Polimerase , Proteínas de Protozoários/genética , Especificidade da Espécie
7.
J Travel Med ; 14(6): 407-10, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17995537

RESUMO

We describe one case of eosinophilic meningitis (EM) in a traveler returning from Santo Domingo, presumably caused by Angiostrongylus cantonensis. Treatment with mebendazole and steroids was effective. The presence of persistent headache, fever, and eosinophilia in travelers who return from developing countries should alert clinicians to the possibility of EM.


Assuntos
Angiostrongylus cantonensis/isolamento & purificação , Eosinofilia/parasitologia , Meningite/parasitologia , Infecções por Strongylida/diagnóstico , Viagem , Adulto , Animais , Antinematódeos/uso terapêutico , Diagnóstico Diferencial , República Dominicana , Eosinofilia/diagnóstico , Eosinofilia/tratamento farmacológico , Glucocorticoides/uso terapêutico , Humanos , Itália , Masculino , Mebendazol/uso terapêutico , Meningite/diagnóstico , Meningite/tratamento farmacológico , Prednisolona/uso terapêutico , Infecções por Strongylida/tratamento farmacológico
8.
BMC Infect Dis ; 6: 177, 2006 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-17176478

RESUMO

BACKGROUND: The number of leishmaniasis cases associated with immunosuppression has increased regularly over the past 20 years. Immunosuppression related to HIV infection, immunosuppressive treatment, organ transplantation, and neoplastic diseases increases the risk for Leishmania-infected people to develop visceral illness. CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. CONCLUSION: Physicians should recognise CS-treated patients as a population likely to be immune-suppressed. In immunodeficiency conditions, unusual forms of leishmaniasis can develop and foster the risk of a diagnostic delay and of poor response to therapy.


Assuntos
Corticosteroides/efeitos adversos , Imunossupressores/efeitos adversos , Leishmania infantum/isolamento & purificação , Leishmaniose Visceral/imunologia , Corticosteroides/imunologia , Corticosteroides/uso terapêutico , Idoso , Animais , Feminino , Humanos , Imunossupressores/uso terapêutico , Leishmaniose Visceral/induzido quimicamente , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/parasitologia , Masculino , Pessoa de Meia-Idade , Células Th1/efeitos dos fármacos , Células Th1/imunologia
9.
Diagn Microbiol Infect Dis ; 72(2): 175-80, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22078908

RESUMO

A new seminested polymerase chain reaction (sn-PCR)-based protocol was developed and used to detect and identify Plasmodium species in 1226 whole-blood samples from patients (872 Italians and 354 foreigners) with at least 1 symptom compatible with clinical malaria. The results were compared with those obtained by microscopy: 187 samples were positive by microscopy for malaria parasites and 196 were positive by sn-PCR. When compared to microscopy, the sn-PCR detected different malaria parasite species in 11 cases. In 4 of 11 cases, the sn-PCR identified 1 additional malaria parasite species not observed microscopically, suggesting increased sensitivity. In 4 samples with levels of parasitemia too low for accurate identification of species by microscopy, the sn-PCR detected 2 P. falciparum, 1 P. ovale, and 1 P. falciparum plus P. ovale. Moreover, 9 negative samples by microscopy were positive by sn-PCR. Follow-up analysis demonstrated a parasite clearance of P. falciparum DNA up to 3 days after the disappearance of parasitemia at microscopy. In conclusion, sn-PCR-based diagnosis of malaria appears to be a useful tool when the results of conventional techniques are negative in the presence of a syndrome consistent with malaria, yielding accurate species identification and consequential correct treatment.


Assuntos
Malária/diagnóstico , Malária/parasitologia , Plasmodium/classificação , Adulto , África/epidemiologia , Ásia/epidemiologia , DNA de Protozoário/classificação , DNA de Protozoário/genética , Feminino , Humanos , Itália/epidemiologia , América Latina/epidemiologia , Malária/epidemiologia , Masculino , Pessoa de Meia-Idade , Plasmodium/genética , Plasmodium/isolamento & purificação , Reação em Cadeia da Polimerase/métodos , Sensibilidade e Especificidade , Especificidade da Espécie , Fatores de Tempo , Viagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA